Now that the news has broke, we're allowed to discuss the findings of Mella/Fluge. In the presentation in London they had out a poster of how they think (and they did emphasis think several times, as they don't know yet - this is only a theory of their's - such as in loose thoughts trying to work out why) the CFS symptoms are mediated. Some respond early and for a long time. Long response. Some respond short and late. Some have no response from two infusions (about 1/3 don't have that) Some respond, and do so for years and years after only two infusions. Why? Their theory is that when the Rituximab is given, it brings down the B-cells, but when that goes down, so does some other immune parameter of which they haven't identified yet. That doesn't mean that it isn't a known immune parameter, it means they don't know which it might be yet. That is displayed as "x" in the graph. The way people get better is displayed with a green line, the higher it goes, the easier are the symptoms. The yellow line indicates the immunlogical thershold x needs to be under for the patient to feel better. It makes perfect sense to me. Although I as well, emphasize that it's a theory. ********** The thoughts they presented at the conference, was that x might be an autoantibody. But they don't know yet. And they emphasized that it's something they're looking at. They had been checking loads of immune parameters before, during and after the infusions, but no clear picture emerged as to what could be behind this.